Phase 3 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 12 and 70 years old (inclusive)
- You have been diagnosed with Hemophilia A or Hemophilia B
- Your inhibitor levels have previously reached 5 BU or higher, and your inhibitor test is positive at the time of enrollment (confirm with trial site)
- You are able to have a needle placed in a vein for treatment
- You have had at least 3 bleeding episodes that needed treatment in the 6 months before your screening appointment
- You agree to use reliable birth control to prevent pregnancy during the trial
- You are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- You have a blood clotting disorder other than Hemophilia
- You plan to receive regular preventative clotting factor treatment during the trial
- You plan to receive the medication Emicizumab during the trial
- You have taken blood-thinning or clot-preventing medications in the 7 days before your first dose, or plan to take them during the trial
- You have a history of blood clots in your arteries or veins
- Your platelet count is below 100×10⁹/L (a measure of blood cells that help clotting) (confirm with trial site)
- Your hemoglobin level (a measure of red blood cells) is below 90g/L (confirm with trial site)
- You have serious liver or kidney disease
- You had a severe bleeding episode within 4 weeks before your first dose
- You had a major surgery or blood transfusion within 4 weeks before your first dose
- You have a known allergy to the study drug STSP-0601
- You are pregnant, breastfeeding, or have a positive pregnancy blood test
- You have taken part in another clinical trial within 4 weeks before enrollment (though trials involving certain clotting factor products may be exceptions — confirm with trial site)
- You have used certain clotting or related medications too recently before your first dose (the exact timeframes depend on the medication — confirm with trial site)
- The trial doctors decide for any other reason that the trial is not appropriate for you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lei Zhang, Ph.D, Hospital of Hematology, Chinese Academy of Medical Sciences
Phone: 010-67519614
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
12 hours effective hemostasis rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.